(secondQuint)Phase I/II Dose Escalation Study of VELCADE and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer.

 This is a dose escalation study, which means that the first group of patients will receive a low dose of PS-341 (VELCADE) and Docetaxel (Taxotere).

 If the low dose of VELCADE and Taxotere appears to be safe, then the next group of patients will receive a higher dose of VELCADE and Taxotere.

.

 Phase I/II Dose Escalation Study of VELCADE and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer@highlight

The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on your cancer.

